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Microsomal triglyceride transfer protein (MTTP) plays a 
critical role in the assembly and secretion of VLDL in the 
liver and chylomicrons in the intestine (1–3). MTTP defi-
ciency results in abetalipoproteinemia, a rare genetic 
disorder resulting in reduced plasma APOB containing 
lipoproteins and increased NAFLD (4). The pharmacolog-
ical inhibition of MTTP is currently being used to treat pa-
tients with homozygous familial hypercholesterolemia, 
helping to significantly reduce LDL-C- and APOB-contain-
ing lipoprotein levels in these patients (5, 6). Of concern, 
pharmacologic MTTP inhibition is associated with signifi-
cant toxicities, including hepatic steatosis and increased 
liver aminotransferase levels (7).
In mice, the genetic deletion of liver MTTP induces he-
patic fat accumulation; however, despite hepatic steatosis, 
these mice demonstrated normal hepatic insulin sensitivity 
(1, 8). In fact, chronic treatment with an MTTP inhibitor 
apparently improved glucose tolerance in Zucker rats (9). 
The metabolically neutral phenotype contrasts with the 
well-established relationship between hepatic lipid accu-
mulation and hepatic insulin resistance in most humans 
with NAFLD and the majority of rodent models of NAFLD 
(10). The mechanism responsible for lipid-induced he-
patic insulin resistance has been attributed to hepatic 
DAG activating PKC, which promotes insulin receptor 
kinase threonine1160 (mouse threonine1150) phosphoryla-
tion, thereby inhibiting insulin-stimulated insulin receptor 
kinase tyrosine phosphorylation (11). There are important 
exceptions to the relationship between hepatic steatosis 
and hepatic insulin resistance in rodents, such as when ex-
cess hepatic lipid is limited to metabolically neutral subcel-
lular compartments (12). Thus, while MTTP inhibition 
clearly lowers plasma lipids and increases hepatic lipids, it 
is unclear how this hepatic steatosis is associated with or 
dissociated from a metabolically deleterious phenotype.
To better understand the effects of MTTP ablation over 
time, we studied both young and aged liver-specific MTTP 
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knockout mice (L-Mttp/), assessing the development of 
lipid-induced hepatic insulin resistance. Furthermore, we 
assessed the content and subcellular localization of different 
stereochemical isoforms of DAG in the liver of L-Mttp/ 
mice. In addition, we assessed the utility of a liver-targeted 
mitochondrial uncoupling agent (13–17) for the treatment 
of hepatic steatosis in L-Mttp/ mice, as there are no cur-
rently available treatments for hepatic steatosis in the setting 
of MTTP deficiency. The orally bioavailable functionally 
liver-targeted controlled-release formulation of 2,4-dinitro-
phenol (controlled-release mitochondrial protonophore; 
CRMP) reverses insulin resistance, hypertriglyceridemia, 
NASH, and diabetes in rodent and nonhuman primate 
models of T2D and NAFLD/NASH (14–17). Therefore, af-
ter assessing the relationship between MTTP ablation and 
lipid-induced hepatic insulin resistance, we administered 
CRMP to evaluate the potential value of liver-targeted mito-
chondrial uncoupling for the treatment of hepatic steatosis 
and hepatic insulin resistance due to reduce MTTP activity.
MATERIALS AND METHODS
Animal care
All experimental procedures were approved by and conducted 
in accordance with the Institutional Animal Care and Use Com-
mittee at Yale University. Liver-specific MTTP knockout mice 
(L-Mttp/) from a C57BL/6 background were generated as de-
scribed previously (18, 19). In all studies, age- and weight-
matched WT (Mttpf/f) mice served as controls. Mice were 
individually housed under controlled temperature (23°C) and 
lighting (12-h light/dark cycle, lights on at 7:00 AM) with free 
access to water and food. Mice were maintained with regular 
chow (Envigo 2108S; 24% protein/58% carbohydrates/18% fat 
calories). Mice were fasted overnight for infusion studies and 6 h 
for basal measurements. Body composition was assessed by 1H 
magnetic resonance spectroscopy using a Bruker BioSpin Mini-
spec analyzer. Energy expenditure, respiratory quotient, oxygen 
consumption (Vo2), carbon dioxide production (Vco2), locomo-
tor activity, and food intake were measured using a comprehen-
sive laboratory animal metabolic system (CLAMS; Columbus 
Instruments). Drinking in the metabolic cages was measured as 
described previously (20). CRMP was mixed in peanut butter (2 
mg/kg) and administered orally; control animals in the CRMP 
treatment experiment received peanut butter plus vehicle. In 
this study, young mice were 10–12 weeks old, whereas aged mice 
were 10 months old.
Glucose tolerance test
Following an overnight fast, mice were injected intraperitone-
ally with 1 g/kg dextrose. Blood samples were taken by tail mas-
sage for glucose and insulin measurements at 0, 15, 30, 60, and 
120 min.
Hyperinsulinemic-euglycemic clamp
Hyperinsulinemic-euglycemic clamps were performed in con-
scious mice as previously described (21). [3-3H]glucose (Perki-
nElmer) was infused at a rate of 0.05 Ci/min for 120 min to 
assess basal turnover. Following the basal infusion, human insulin 
(Novo Nordisk) was given as a prime [7.14 mU/(kg-min) × 3 min] 
and then continuous [2.5 mU/(kg-min)] infusion along with 
a variable infusion of 20% dextrose to maintain euglycemia 
(100–120 mg/dL) and [3-3H]glucose at a rate of 0.1 Ci/min. 
Plasma samples were obtained by tail massage at 0, 25, 45, 65, 80, 
90, 100, 110, 120, 130, and 140 min. At the end of the study, mice 
were euthanized with a sodium pentobarbital injection (4 mg/
mouse), and tissues taken were snap-frozen in liquid nitrogen and 
stored at 80°C for subsequent use.
Plasma assays
Plasma glucose was measured using a YSI 2700D glucose ana-
lyzer (Yellow Springs Instruments). Standard kits were used to 
measure plasma nonesterified fatty acids (Wako) and triglycerides 
(Sekisui). Insulin concentrations were determined by radioimmu-
noassay (EMD Millipore).
Liver lipid measurements
Tissue triglycerides (TAGs) were extracted using the method 
of Bligh and Dyer (22) and measured using a standard kit 
(Sekisui). For subcellular compartment-specific DAG extraction, 
liver tissue was homogenized with a Doucne-type homogenizer in 
Buffer A [250 mM sucrose, 10 mM Tris (pH 7.4), 0.5 mM EDTA]. 
The full extraction was performed on ice or at 4°C. The homog-
enate was centrifuged at 17 K rcf for 15 min to obtain superna-
tant 1 and pellet 1. Supernatant 1 was centrifuged at 387 K rcf for 
75 min; the resultant pellet contained ER membrane lipids, the 
top layer of the supernatant contained lipid droplet lipids, and 
the middle of the supernatant contained cytosolic lipids. Pellet 1 
was resuspended in Buffer A, layered on top of a 1.12 M sucrose 
solution, and centrifuged at 111 K rcf for 20 min to obtain pellet 
2 and supernatant 2. Pellet 2 was resuspended in Buffer A and 
centrifuged at 17 K rcf for 15 min; the resultant pellet contained 
mitochondrial membrane lipids. The interfacial layer of superna-
tant 2 was taken and diluted with Buffer A and centrifuged at 59 
K rcf for 9 min; the resultant pellet contained plasma membrane 
lipids.
The separation and quantitation of DAG stereoisomers were 
performed by LC-MS/MS using electrospray ionization on an AB 
Sciex Qtrap 6500 interfaced to a Shimadzu UFLC using Luna 5u 
Silica (100 Å, 250 × 2.0 mm) and LUX 5u Cellulose-1 (250 × 4.6 
mm) columns connected in series with an isocratic solvent of hex-
ane-isoproponal (300:7). DAG stereoisomer standards were used 
to establish retention times and responses relative to the internal 
standard (C17, C17-DAG). No additional separation following 
subcellular fractionation was done prior to LC-MS/MS analysis to 
avoid racemization. DAG content is expressed as the sum of indi-
vidual species. Hepatic ceramide content was measured as previ-
ously described (23).
Immunoblotting analysis
Tissue was homogenized in ice-cold homogenization buffer 
with protease and phosphatase inhibitors (Complete MINI + 
PhosSTOP; Roche). Protein extracts (30 µg) were separated by a 
4%–12% gradient SDS-PAGE (Invitrogen) and then transferred 
to a PVDF membrane (Millipore) using a semidry transfer cell 
(Bio-Rad) for 2 h. After blocking with 5% nonfat dry milk in TBST 
[10 mM Tris (pH 7), 100 mM NaCl, 0.1% Tween 20], membranes 
were incubated overnight at 4°C with primary antibodies. Mem-
branes were thoroughly washed and incubated with the appropri-
ate secondary antibody (Cell Signaling Technology), and immune 
complexes were detected using an enhanced luminol chemilu-
minescence system (Thermo Fisher Scientific) and exposed to 
photographic film. Immunoblots were quantified by optical den-
sitometry. For PKC translocation, cytoplasm and plasma mem-
brane were separated by ultracentrifugation as previously described 
(24, 25) prior to Western blotting. Insulin receptor , phosphory-
lated insulin receptor , Akt, phosphorylated Akt (Ser473), IRE1, 
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phosphorylated eiF2, and GAPDH antibodies were purchased 
from Cell Signaling Technology. Sodium potassium ATPase and 
phosphorylated IRE1 antibodies were purchased from Abcam 
Inc. PKC antibody was purchased from BD Biosciences. Anti-
body against eiF2 was purchased from Santa Cruz Biotechnology. 
KDEL (GRP 78 and GRP 94) antibody was purchased from Enzo 
Life Science.
Markers of liver inflammation
Inflammatory cytokines were measured in liver homogenates 
by ELISA (Qiagen) and normalized to total protein content by 
a standard Coomassie-based absorption assay (Thermo Fisher 
Scientific).
Statistical analysis
All data are expressed as means ± SEMs. Results were assessed 
using a two-tailed unpaired Student t-test or two-way ANOVA fol-
lowed by Tukey’s multiple comparison test (Prism 7; GraphPad 
Software, Inc.). P < 0.05 was considered significant.
RESULTS
Young L-Mttp/ mice exhibit hepatic steatosis without 
excess sn-1,2-DAG at the plasma membrane
Hepatic triglyceride was measured in 10–12-week-old 
L-Mttp/ mice and Mttpf/f WT controls. As expected, hepatic 
Fig. 1. Young L-Mttp/ mice develop hepatic steatosis without the accumulation of plasma membrane sn-1,2-DAGs. A: Liver TAG content. 
B: Liver ceramide content. C: Total DAG. D–F: sn-1,2-DAG (D), sn-1,3-DAG (E), and sn-2,3-DAG (F) content in five compartments of the liver 
from young WT and L-Mttp/ mice: plasma membrane (PM), mitochondrial (Mito), ER, lipid droplet (LD), and cytosol (Cyto). Individual 
statistical comparisons were evaluated by Student’s two-tailed t-test. Data are means ± SEMs of n = 6–8 per group.
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TAG was significantly increased in young L-Mttp/ mice 
(Fig. 1A). DAGs and ceramides are two bioactive lipid me-
tabolites that are thought to link hepatic steatosis to he-
patic insulin resistance. Hepatic ceramides and DAGs were 
both increased in young L-Mttp/ mice (Fig. 1B, C). DAG 
accumulation causes hepatic insulin resistance through the 
activation of PKC that results in phosphorylation of the 
insulin receptor threonine11160, which in turn leads to 
the inhibition of insulin receptor tyrosine kinase activity 
(10, 11, 26). It has recently been shown that sn-1,2-DAG at 
the plasma membrane is the entity that drives PKC translo-
cation and insulin resistance (27); thus, we measured sn-
1,2-DAGs as well as the other DAG stereoisomers in five 
intracellular compartments. Using this approach, we found 
that sn-1,2-DAGs were increased in the lipid droplet, cyto-
sol, ER, and mitochondrial compartments but not the 
plasma membrane compartment (Fig. 1D–F) of young L-
Mttp/ mice.
Liver insulin sensitivity is preserved in young L-Mttp/ 
mice
We also assessed whole-body and tissue-specific insulin 
action by hyperinsulinemic-euglycemic clamp studies in 
10–12-week-old L-Mttp/ mice. Whole-body insulin sensi-
tivity of young L-Mttp/, mice, as reflected by the glucose 
infusion rate required to maintain euglycemia, was not dif-
ferent compared with WT mice (Fig. 2A, B). Furthermore, 
insulin-stimulated peripheral glucose disposal was not 
changed (Fig. 2C). Additionally, insulin-mediated suppres-
sion of endogenous glucose production (EGP) was also not 
altered in young L-Mttp/mice, indicating unchanged he-
patic insulin sensitivity (Fig. 2D, E). Thus, MTTP deficiency 
does not alter hepatic or peripheral insulin action in young 
mice despite marked hepatic steatosis and increases in sn-
1,2-DAGs in the lipid droplet fraction.
PKC activation links hepatic DAG accumulation to he-
patic insulin resistance. Young L-Mttp/ mice displayed no 
change in hepatic PKC membrane translocation, a surro-
gate for PKC activation, compared with WT mice (Fig. 
2F), consistent with the unchanged sn-1,2-DAG in the 
hepatic plasma membrane. Furthermore, insulin-stimulated 
protein kinase B (Akt) phosphorylation was not changed, 
reflecting preserved hepatic insulin signaling in young L-
Mttp/ mice (Fig. 2G).
Aged L-Mttp/ mice demonstrate CRMP-reversible 
glucose intolerance
We evaluated 10-month-old L-Mttp-/ mice and WT con-
trols to gauge the metabolic impact of the interaction be-
tween aging and hepatic Mttp deficiency. We first evaluated 
L-Mttp-/ mice by intraperitoneal glucose tolerance testing. 
Although the excursion in plasma glucose concentration 
was not altered during glucose tolerance testing (Fig. 3A, 
B), the plasma insulin excursions were much higher in 
aged L-Mttp/ mice. These changes in plasma insulin with 
normal plasma glucose concentrations are a more sensitive 
Fig. 2. Normal whole-body insulin sensitivity in 
young L-Mttp/ mice. A, B: Plasma glucose concen-
trations (A) and glucose infusion rate (B) during the 
hyperinsulinemic portion of the clamp study. C: 
Whole-body insulin-stimulated peripheral glucose me-
tabolism. D: Endogenous glucose production. E: Insu-
lin-mediated suppression of endogenous glucose 
production. F: PKC translocation in the liver. G: Liver 
AKT phosphorylation comparing basal and insulin-
stimulated liver. Statistical comparisons were made by 
unpaired two-way Student’s t-test. Data are means ± 
SEMs of n = 7–8 per group.
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measure of hepatic insulin resistance during a glucose tol-
erance test, and these insulin excursions were higher in 
aged L-Mttp/ mice (Fig. 3C, D). To determine whether 
insulin resistance could be reversed with a liver-targeted 
mitochondrial uncoupler to decrease liver fat content, we 
treated L-Mttp/ mice with the controlled-release form of 
2,4-dinitrophenol, CRMP. CRMP-treated L-Mttp/ mice 
were more glucose-tolerant than untreated L-Mttp/ mice, 
as reflected by 20%–30% reductions in plasma glucose and 
insulin concentrations during the intraperitoneal glucose 
tolerance test. (Fig. 3A–D).
Hepatic steatosis and PKC activation in aged L-Mttp/ 
mice are blunted by CRMP administration
We evaluated plasma and hepatic lipid content in our 
aged WT, L-Mttp/, and CRMP-treated L-Mttp/ mice. 
Fasting plasma TAG was decreased by 70% in L-Mttp/ 
versus WT mice; this lower level of plasma TAG was unaf-
fected by CRMP intervention (Fig. 4A). Hepatic TAG was 
increased in L-Mttp/ versus WT mice; 4 weeks of CRMP 
treatment decreased hepatic TAG in L-Mttp/ mice by 
15% (Fig. 4B). Hepatic ceramide levels were increased in 
aged L-Mttp/ mice; however, these levels were not 
changed by CRMP treatment (Fig. 4C). In contrast, total 
DAG was increased in aged L-Mttp/ mice, and this in-
crease was dramatically blunted with CRMP treatment (Fig. 
4D). We assessed DAG stereoisomers in five subcellular 
compartments. In the aged L-Mttp/ mice, sn-1,2–DAG 
content was increased in all subcellular compartments, 
contrasting with the young L-Mttp/ mice. The increase in 
DAG was attenuated by CRMP treatment (Fig. 4E–G). 
PKC membrane translocation was increased in aged 
L-Mttp/ mice, and this increase in PKC activation was 
reversed by CRMP treatment (Fig. 4H). Thus, CRMP treat-
ment effectively reduced the accumulation of hepatic TAG 
and DAG content in aged L-Mttp/ mice. Given our previ-
ous results it is likely that the decrease in plasma membrane 
sn-1,2-DAG accounts for the decrease in PKC activation in 
these aged L-Mttp/ mice (27).
Whole-body energy balance was not altered by L-Mttp/ 
genotype or CRMP treatment
To examine whether the deficiency of MTTP in the liver 
has an effect on whole-body energy balance, we performed 
metabolic cage studies with aged WT mice, aged L-Mttp/ 
mice, and aged L-Mttp/ mice treated with CRMP. Neither 
deficiency of MTTP nor CRMP treatment altered body 
weight (Fig. 5A). Consistent with the matched body weights, 
there were no differences in oxygen consumption, carbon 
dioxide production, respiratory quotient, energy expendi-
ture, feeding, and activity during metabolic cage studies in 
any of the three groups (Fig. 5B–G). Thus, while we ob-
served significant differences in glucose tolerance between 
aged WT and L-Mttp/ mice and between L-Mttp/ mice 
with and without CRMP treatment, these differences were 
not associated with changes in whole-body energy balance, 
body weight, or activity.
Liver inflammation and ER stress were not changed in 
aged L-Mttp/ mice
Inflammation and ER stress are major factors that pro-
mote insulin resistance (28, 29). We assessed whether 
Fig. 3. Aged L-Mttp/ mice demonstrated glucose 
intolerance that improved with CRMP. A, B: Plasma 
glucose concentration time course (A) and area under 
the glucose versus time curve (B) during intraperito-
neal glucose tolerance tests. C, D: Plasma insulin con-
centration time course (C) and area under the insulin 
versus time curve (D) during intraperitoneal glucose 
tolerance tests. Mice were fasted overnight before the 
glucose tolerance tests. Data are represented as means 
± SEMs. Statistical comparisons were made by two-way 
ANOVA. Data are means ± SEMs of n = 7–8 per group.
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inflammatory changes were associated with the alterations 
in insulin action observed in aged L-Mttp/ mice. Hepatic 
proinflammatory and antiinflammatory cytokine content 
was measured: IL1, IL1, IL2, IL4, IL6, IL10, and IL12 
were not changed in aged L-Mttp/ mice (Fig. 6A) com-
pared with WT mice. We also assessed for any changes in 
ER stress that might also contribute to the observed changes 
in hepatic insulin action in aged L-Mttp/ mice. ER stress 
Fig. 4. Hepatic steatosis, hepatic plasma membrane sn-1,2 DAG accumulation, and increased PKC membrane translocation were all ob-
served in aged L-Mttp/ mice. A: Plasma TAG concentration. B: Liver TAG content. C: Liver ceramide content. D: Liver total DAG. E–G: 
sn-1,2-DAG (E), sn-1,3-DAG (F), and sn-2,3-DAG (G) content in five hepatic subcellular compartments from aged WT mice, aged L-Mttp/ 
mice, and aged L-Mttp/ mice treated with CRMP: plasma membrane (PM), mitochondrial (Mito), ER, lipid droplet (LD), and cytosol 
(Cyto). H: Hepatic PKC translocation. Statistical comparisons were made by two-way ANOVA. Data are means ± SEMs of n = 6–8 per group.
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markers were assessed by immunoblotting and were not al-
tered in the liver tissue of aged L-Mttp-/mice and aged L-
Mttp-/mice treated with CRMP (Fig. 6B–F). Thus, changes 
in liver inflammation and changes in ER stress do not ap-
pear to account for the changes in glucose tolerance we 
observed in aged L-Mttp/ mice.
CRMP reversed hepatic insulin resistance in aged 
L-Mttp/ mice
Taken together, the observed differences in hepatic 
DAG content and hepatic PKC activation suggest that the 
improvement in glucose tolerance in aged L-Mttp/ mice 
treated with CRMP is due to a reversal in lipid-induced he-
patic insulin resistance. To demonstrate this definitively, 
we performed hyperinsulinemic-euglycemic clamps on 
aged L-Mttp/ mice treated for 4 weeks with CRMP or ve-
hicle. CRMP-treated mice showed a significant improve-
ment in whole-body insulin sensitivity, reflected by an 
increased glucose infusion rate during the clamp (Fig. 7A, 
B). Insulin-stimulated peripheral glucose disposal was not 
changed (Fig. 7C). Insulin-mediated suppression of EGP 
was significantly increased in CRMP-treated mice, indicat-
ing improved hepatic insulin responsiveness (Fig. 7D, E). 
Consistent with changes in hepatic insulin sensitivity, insu-
lin-stimulated protein kinase B and insulin receptor kinase 
phosphorylation were significantly increased in the liver 
tissues of L-Mttp/ mice treated with CRMP (Fig. 7F, G). 
Taken together these results demonstrate that CRMP’s 
ability to improve glucose tolerance in aged L-Mttp/ mice 
could mostly be attributed to the reversal of hepatic insulin 
resistance.
DISCUSSION
MTTP inhibitors have been shown to reduce circulating 
VLDL and LDL in animal models and human subjects (2, 
30, 31) and thus are a valuable addition to the pharmaco-
poeia for patients with severe hypertriglyceridemia. How-
ever, the promise of MTTP-targeted therapeutics has been 
questioned, as hepatic MTTP inhibition or MTTP defi-
ciency induces hepatic steatosis and transaminitis (8, 32, 
33). NAFLD is of great clinical concern, both as a precur-
sor to nonalcoholic steatohepatitis and as a cause of he-
patic insulin resistance (34). Prior investigations have 
observed that MTTP knockout mice develop hepatic ste-
atosis, with increased DAG and ceramide content but with-
out the development of hepatic insulin resistance or 
glucose intolerance (1). Furthermore, treating Zucker fatty 
rats with an MTTP inhibitor not only improved their glu-
cose tolerance but also decreased fasting plasma glucose 
and insulin concentrations (9), consistent with a reversal of 
insulin resistance. Until now, there has been no explana-
tion for the discordance between hepatic bioactive lipid 
content and hepatic insulin action in these models. Our 
study both recapitulates and explains these findings. We 
found that L-Mttp/ mice develop hepatic steatosis at an 
early age but do not develop hepatic insulin resistance. 
However, we also found that with aging, L-Mttp/ (10-
month-old) mice do indeed develop hepatic insulin resis-
tance. The discordant metabolic phenotypes of the young 
and aged L-Mttp/ mice were explained well in the con-
text of the DAG-PKC hypothesis of lipid-induced hepatic 
insulin resistance (34, 35); the key to understanding the 
phenotype of these mice was an analysis of the DAG stereo-
isomer content separated by subcellular compartment. 
Both young and aged L-Mttp/ mice had increased total 
hepatic DAG content, but only the aged mice demon-
strated increases in plasma membrane sn-1,2-DAG and 
PKC activation.
The DAG-nPKC model helps to explain lipid-induced 
insulin resistance in multiple tissues (34, 35). The results 
from this study support this hypothesis, wherein sn-1,2-
DAG accumulation in the hepatic plasma membrane drive 
plasma membrane PKC recruitment and activation. Acti-
vated PKC in turn phosphorylates threonine1160 in the ty-
rosine kinase active site of the insulin receptor, destabilizing 
Fig. 5. Whole-body energy balance was not different 
between aged WT mice, aged L-Mttp/ mice, and 
aged L-Mttp/ mice treated with CRMP. A: Body 
weight. B: Oxygen consumption (VO2). C: Carbon di-
oxide production (VCO2). D: Respiratory exchange ra-
tio. E: Energy expenditure throughout the day. F: 
Food intake. G: Daily activity. Statistical comparisons 
were made by two-way ANOVA. Data are means ± 
SEMs of n = 6 per group.
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this site and disrupting insulin receptor tyrosine kinase ac-
tivity (10, 11). Thus, in the setting of increased hepatic 
plasma membrane sn-1,2-DAG more insulin must bind the 
hepatic insulin receptor to drive the multiple downstream 
hepatocellular actions of insulin; that is, the liver is insulin-
resistant. Of note, there are models that dissociate hepatic 
lipids from hepatic insulin resistance. Some, such as sobeti-
rome (a thyroid hormone receptor- agonist) treated ro-
dents, demonstrate increased hepatic glucose production 
despite reduced hepatic lipids due to the increased flux of 
gluconeogenic precursors (36). Others, such as the CGI58 
knockdown mouse, demonstrate increased hepatic DAG 
content but no increase in PKC activation due to the stor-
age of DAG in lipid droplets, which represent a neutral 
compartment (12, 37). The lack of hepatic insulin resis-
tance in the L-Mttp/ mouse appears to be consistent with 
this latter mechanism. Consistent with prior studies of the 
L-Mttp/ mouse (1), in the young L-Mttp/ mouse we ob-
served increased hepatic bioactive lipid species without an 
increase in hepatic insulin resistance. To explain this dis-
crepancy between hepatic lipid and hepatic insulin resis-
tance, we fractionated the DAGs both by subcellular 
compartment and by stereochemistry, as PKCs are thought 
to be activated by plasma membrane sn-1,2-DAG (27, 38–
40) and not by DAGs in other compartments or 1,3- or 2,3-
DAG stereoisomers. The sn-1,2-DAG stereoisomer content 
was not increased in the plasma membrane from the livers 
of these mice, explaining the insulin-sensitive hepatic ste-
atosis phenotype. Furthermore, in contrast with both prior 
studies of young L-Mttp/ mice and our study of young 
L-Mttp/ mice, in aged L-Mttp/ mice we saw increased 
hepatic insulin resistance, along with a concomitant in-
crease in plasma membrane sn-1,2-DAG content. These 
patterns correlating plasma membrane DAG content with 
hepatic insulin resistance were most clearly observed with 
sn-1,2-DAG stereoisomers. Thus, we found hepatic insulin 
resistance and PKC activation was dissociated from he-
patic steatosis and total TAG/DAG content in young 
L-Mttp/ mice, as the sn-1,2-DAGs were stored in neutral 
compartments (mostly lipid droplets) in these mice, while 
hepatic insulin resistance developed in the older L-Mttp/ 
mice as sn-1,2-DAGs accumulated in the plasma mem-
brane, leading to PKC activation and decreased hepatic 
insulin signaling at the level of the insulin receptor.
The discrepancy between the DAG localization and 
the phenotypes of the young versus old mice may provide 
Fig. 6. Liver inflammatory markers and activation of the unfolded protein response were unaltered by genotype or drug treatment in aged 
L-Mttp/ mice and L-Mttp/ mice treated with CRMP. A: Hepatic cytokine concentrations. B: ER stress/unfolded protein response markers 
assessed by immunoblot. C: GRP78. D: GRP94. E: Phosphorylation of eIF2. F: Phosphorylation of IRE1. Statistical comparisons were made 
by two-way ANOVA. Data are means ± SEMs of n = 3 per group.
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insight into how DAGs are trafficked from the ER to the 
plasma membrane. Our results suggest that DAG transport 
from the ER to the plasma membrane may occur by multi-
ple pathways. DAG would accumulate rapidly during VLDL 
secretion and more slowly by pathways independent of 
VLDL secretion. This model could be tested by application 
to other genetic variants associated with defective VLDL 
secretion. Mutations in APOB and TM6SF2 both lead to 
Fig. 7. CRMP treatment improved hepatic insulin sensitivity of aged L-Mttp/ mice as assessed by hyperinsulinemic-euglycemic clamps. A: 
Plasma glucose during the clamp. B: Glucose infusion rate during the clamp. C: Insulin-stimulated peripheral glucose metabolism. D: EGP in 
both the basal and hyperinsulinemic clamped state. E: Insulin-mediated suppression of EGP represented as percentage suppression. F: Liver 
AKT phosphorylation under basal and insulin-stimulated conditions. G: Liver insulin receptor  (insulin receptor kinase; IRK) phosphorylation 
under basal and insulin-stimulated conditions. Statistical comparisons made by Student’s t-test. Data are means ± SEMs of n = 6–7 per group.
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defective VLDL secretion and reduced LDL-C and are as-
sociated with human disease. APOB mutations cause famil-
ial hypobetalipoproteinemia, while TM6SF2 mutations are 
associated with NAFLD and progression to NASH (41–44). 
Apob mutant mice are quite phenotypically similar to 
MTTP-deficient mice, developing hepatic steatosis (41) 
without a disruption in glucose or insulin tolerance (42). 
While the protection against insulin resistance seen in 
ApoB mice may be due to a reduction in the delivery of 
TAG to the muscle and reduced peripheral insulin resis-
tance, it would be reasonable to speculate that animals with 
defective VLDL secretion may be slower to develop hepatic 
insulin resistance due to a reduction in DAG transporta-
tion from the ER to the plasma membrane. The assessment 
of hepatic insulin action and plasma membrane DAG con-
tent in young and older ApoB and Tm6sf2 mutant mice 
would help to test a multipathway model of DAG transport 
from ER to plasma membrane.
The MTTP inhibitor lomitapide has been approved to 
treat patients with homozygous familial hypercholesterol-
emia; however, this approach induces hepatic fat accumu-
lation and increased plasma transaminases (5, 7, 45). The 
use of lomitapide is associated with increased circulating 
transaminases, and this medication carries a boxed warn-
ing regarding hepatotoxicity. If the hepatic fat accumula-
tion associated with MTTP inhibition can be prevented, 
the hepatotoxicity of the drug class may be attenuated. In 
this study, we examined the effect of a functionally liver-
targeted mitochondrial protonophore, CRMP (14), in 
aged L-Mttp/ mice. We found that CRMP treatment re-
versed hepatic fat accumulation and improved glucose tol-
erance in aged L-Mttp/ mice. Consistent with these 
improvements in hepatic steatosis and in glucose toler-
ance, CRMP treatment markedly increased both whole-
body insulin responsiveness and hepatic insulin sensitivity. 
The improvements in hepatic insulin sensitivity were asso-
ciated with reductions in plasma membrane sn-1,2-DAG 
content, PKC activation, and normalized insulin signaling 
from the insulin receptor through Akt in aged L-Mttp/ 
mice. In contrast, there were no changes in hepatic ce-
ramide content despite the reversal of hepatic insulin resis-
tance with CRMP treatment. Thus, while liver-specific aged 
L-Mttp/ mice developed hepatic insulin resistance, this 
defect in hepatic insulin action was reversible by CRMP 
treatment. These findings offer further evidence for the 
role of plasma membrane sn-1,2-DAG -induced PKC acti-
vation in causing hepatic insulin resistance and support the 
potential utility of CRMP and other liver-targeted mito-
chondrial protonophores for the treatment of NAFLD as-
sociated with reduced MTTP activity. These results also 
dissociate hepatic ceramide content from hepatic insulin 
resistance in these CRMP-treated L-Mttp/ mice, demon-
strating that ceramides are involved in causing hepatic in-
sulin resistance in this model.
Taken together, these data demonstrate that differences 
in the intracellular compartmentation of sn-1,2-DAGs in 
the lipid droplet versus plasma membrane explain the dis-
sociation of NAFLD and lipid-induced hepatic insulin resis-
tance in young L-Mttp/ mice as well as the development 
of lipid-induced hepatic insulin resistance in aged L-Mttp/ 
mice. Consistent with the key role for plasma membrane 
sn-1,2-DAG-induced PKC activation in causing hepatic in-
sulin resistance in the aged L-Mttp/ mice, we show that 
liver-targeted mitochondrial uncoupling with CRMP re-
verses hepatic steatosis, plasma membrane sn-1,2-DAG ac-
cumulation, hepatic PKC activation, and hepatic insulin 
resistance in these mice.
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